Glucosamine suppresses proliferation of human prostate carcinoma DU145 cells through inhibition of STAT3 signaling by Chesnokov, Viktor et al.
BioMed  Central
C
TIONAL INTERNA
CANCER CELL
Page 1 of 11
(page number not for citation purposes)
Cancer Cell International
Open Access Primary research
Glucosamine suppresses proliferation of human prostate carcinoma 
DU145 cells through inhibition of STAT3 signaling
Viktor Chesnokov, Chao Sun and Keiichi Itakura*
Address: Department of Molecular Biology, Beckman Research Institute of the City of Hope, 1450 East Duarte road, Duarte, California 91010, USA
Email: Viktor Chesnokov - vchesnokov@coh.org; Chao Sun - csun@coh.org; Keiichi Itakura* - kitakura@coh.org
* Corresponding author    
Abstract
Background:  Glucosamine is known as a toxic agent for several malignant cell lines and
transplanted tumors with little toxicity to normal host tissues. However, the mechanisms
underlying anticancer activity of glucosamine are poorly understood. To study the mechanisms, the
human prostate cancer DU145 cells were used for the model.
Results: Glucosamine at concentration 2 mM suppressed proliferation and induced death of
DU145 cells. Detailed analysis showed that glucosamine decreased DNA synthesis, arrested cell
cycle at G1 phase and induced apoptosis. The effects of glucosamine were associated with up-
regulation of p21waf1/cip, a CDK inhibitor. Our further studies identified glucosamine as an
inhibitor of signal transducer and activator of transcription (STAT) 3 which is constitutively
activated in many cancer cells including DU145 cells. Glucosamine inhibited phosphorylation of
STAT3 at the Tyr705 residue and as a result, reduced STAT3 DNA binding and transcriptional
activities. Indeed, the expression of apoptosis inhibitor survivin, which is well known target of
STAT3, was suppressed. Contrary to DU145 cells, glucosamine did not affect proliferation of other
human prostate cancer PC-3 and C4-2B cells, in which STAT 3 signal pathway is not constitutively
active.
Conclusion: Our data identifies glucosamine as a suppressor of STAT3 signaling and suggests that
anticancer activity of glucosamine may be attributed to the suppression of STAT3 activity. Potential
application of glucosamine for the treatment of tumors with constitutively active STAT3 is
proposed.
Background
D-Glucosamine (2-amino-2-deoxy-D-glucose) is a natu-
rally occurring amino monosaccharide and is an essential
carbohydrate component of glycoproteins, glycolipids,
and glycosaminoglycans. In vivo, glucosamine is synthe-
sized in the phosphorylated form glucosamine-6-phos-
phate (glucosamine-6-P) from fructose-6-phosphate
(fructose-6-P) and glutamine by glucosamine: fructose-6-
phosphate amidotransferase, which is the first and rate-
limiting step of the hexosamine biosynthetic pathway
(HBP). In humans, the endogenous production of glu-
cosamine is in ranges from 4 to 20 g/day [1]. Exogenous
glucosamine is actively transported into the animal cells
by glucose transporters (GLUTs) [2], and phosphorylated
to glucosamine-6-P by hexokinase. Glucosamine-6-P is
converted either back to fructose-6-P by deamination for
glycolysis pathway [3], or to UDP-N-acetylglucosamine
which serves as a donor of N-acetylglucosamine (GlcNAc)
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for O- or N-linked protein glycosylation [4]. Glucosamine
is one of the most popular dietary supplements sold in the
United States to ease symptoms of pain related to osteoar-
thritis [5]. Anticancer activity of glucosamine was first
demonstrated more than 50 years ago [6]. Glucosamine is
toxic to several malignant cell lines in vitro, and an effec-
tive lytic agent for several types of transplanted tumors in
vivo, with little toxicity to normal host tissues [7]. It has
been shown that glucosamine induces multiple biochem-
ical and cellular effects including depletion of cellular
nucleotide pools, inhibition of protein, RNA and DNA
synthesis, and alterations of plasma and intracellular
membranes [8]. Recent in vitro studies have demonstrated
that glucosamine induces apoptosis and suppresses prolif-
eration of the SMMC-7721 hepatoma [9] and K562 leuke-
mia cells [10]. However, the molecular mechanisms
underlying anticancer activity of glucosamine are still
poorly understood.
Signal transducers and activators of transcription (STAT)
are the latent transcription factors that mediate cellular
responses to cytokines and growth factors [11]. Some
members of the STAT protein family, particularly STAT3
and STAT5, regulate several oncogenic processes such as
proliferation, survival, angiogenesis and immune
response [12], and activated STAT3 pathway is frequently
found in different human tumors [12] including prostate
cancer [13]. Suppressing STAT3 signaling pathway causes
growth inhibition and apoptosis of cancer cells [14-16],
therefore STAT3 represents a validated target for cancer
therapy [12,17]. Prostate cancer is the most common can-
cer among men in USA, comprising one-third of all new
cancer cases each year, and is the second leading cause of
cancer-related death in males (over 30,000 per year) [18].
Despite significant advances in surgical techniques and
treatment options including androgen ablation therapy,
radiotherapy and chemotherapy [19], the recorded
number of prostate cancer deaths in United States has not
changed from 1989 to 2002 [18]. At present, there is no
effective treatment for hormone-refractory prostate cancer
which typically develops after androgen ablation therapy
[20]. Thus, continued search for the novel prevention and
treatment strategies is inevitable.
The goal of the present study was to investigate mecha-
nisms underlying anti-cancer activity of glucosamine in
human prostate cancer cells. We found that glucosamine
inhibited DNA synthesis, induced cell-cycle arrest at G1
phase and stimulated apoptosis in the human prostate
cancer DU145 cells. Our studies identified glucosamine as
a previously unrecognized suppressor of STAT3 signaling
pathway. In DU145 cells, STAT3 is constitutively activated
and is required for cell proliferation and survival. Glu-
cosamine inactivated STAT3 by suppressing phosphoryla-
tion at the Tyr705 residue, thereby inhibiting the DNA
binding and transcriptional activities, and suppressing its
downstream gene expression survivin, an inhibitor of
apoptosis. As expected, glucosamine has almost no effects
on proliferation of human prostate cancer PC-3 and C4-
2B cells, in which STAT3 is not constitutively active. How-
ever, similar to DU145 cells, the proliferation of Hela cells
harboring constitutively activated STAT3 is suppressed by
glucosamine treatment.
Results
Glucosamine inhibits DU145 cells proliferation
To examine anti-tumor effects of glucosamine on human
prostate cancer cells, the hormone refractory human pros-
tate carcinoma DU145 cells were plated and treated with
glucosamine at concentrations 1, 2, and 4 mM for 2 and 3
days. The cells attached to culture flasks were collected
and cell numbers were counted using hemocytometer. As
shown in Fig. 1A, glucosamine inhibited the proliferation
of DU145 cells in a dose-dependent manner. With 1 mM
glucosamine, the cell numbers were reduced to 50 and
70% of those of the untreated controls for 2 and 3 days,
respectively, and with 2 and 4 mM glucosamine cell pro-
liferation were completely suppressed for 2 and 3 days
(Fig. 1A). Since effects of glucosamine on cell prolifera-
tion was evident at 2 mM, all subsequent experiments
were performed using this concentration unless specified
otherwise.
Glucosamine inhibits DNA synthesis and arrests cell cycle 
progression from G1 to S in DU145 cells
We analyzed the effects of glucosamine on DNA synthesis
by measuring the rate of BrdU incorporation into newly
synthesized DNA after culturing cells in the presence of 1,
2 or 4 mM glucosamine for 6, 14, and 24 h. The dose-
dependent decrease of BrdU incorporation was observed
at 2 mM and 4 mM concentrations examined at all time
points, and the inhibition of DNA synthesis became more
significant with the duration of the treatment (Fig. 1B).
However, glucosamine at 1 mM did not significantly
affect DNA synthesis. This data suggests that the decrease
of cell numbers at 1 mM concentration (Fig. 1A) is the
result of the increase of cell death rather than the inhibi-
tion of cell proliferation. Using the same experimental
design, we examined whether DNA synthesis in DU145
cells is inhibited by two other hexosamines, galactos-
amine and mannosamine. In contrast to glucosamine,
neither galactosamine nor mannosamine at 2 or 4 mM
concentration had any apparent effect on BrdU incorpora-
tion (data did not show) indicating the specific role of
glucosamine in DNA synthesis inhibition. Furthermore,
we analyzed potential effects of glucosamine on cell-cycle
progression. DU145 cells were treated in early log-phase
with 4 mM glucosamine for 24 h and cell cycle phase dis-
tribution was analyzed by flow cytometry. The treatment
increased the percentage of cells present in G1 phase fromCancer Cell International 2009, 9:25 http://www.cancerci.com/content/9/1/25
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50% to 73%, and reduced that of S-phase cells from 46%
to 25%, and G2M cells from 4% to 2% (Fig. 1C). These
results indicate that inhibition of DNA synthesis and cell
cycle arrest at G1-S transition play major rolls in the inhi-
bition of cell proliferation by glucosamine.
Glucosamine induces p21Waf1/Cip expression in DU145 cells
To examine the mechanisms of glucosamine-induced cell
cycle arrest, we analyzed the expression of cyclin-depend-
ent kinase (CDK) inhibitors p21Waf1/Cip and p27Kip1, pro-
teins that could arrest cell cycle progression at both G1
and G2 phases [21]. Treatment of DU145 cells with 2 mM
glucosamine for 48 h significantly increased the p21 pro-
tein (Fig. 2A). To study the regulation of p21 expression,
we measured the steady state level of the p21 mRNA in
DU145 cells. Northern blot analysis of the total RNA from
the treated DU145 cells showed that glucosamine
increased the p21 mRNA in a time-dependent manner
(Fig. 2B). In contrast, p27 mRNA levels were decreased by
this treatment (data not shown.
To explore the possibility that glucosamine affects the p21
promoter activity, we transiently transfected DU145 cells
Glucosamine-induced inhibition of growth of DU145 cells Figure 1
Glucosamine-induced inhibition of growth of DU145 
cells. A, DU145 cells were cultured in the absence or pres-
ence of 1, 2, or 4 mM glucosamine for 2 or 3 days in 24-well 
plates. Total number of cells for each well was counted using 
a hemocytometer. B, BrdU incorporation into DNA of 
DU145 cells treated with 1, 2, or 4 mM glucosamine for 6, 
14, or 24 h is present as % of control without glucosamine. 
C, Flow cytometry analysis of distribution of DU145 cells in 
different phases of cell cycle after treatment with 4 mM glu-
cosamine for 24 h. The results of the representative experi-
ment are presented as mean ± standard deviation of the 
three independent samples. All experiments were repeated 
at least three times.
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Induction of the p21/WAF1 expression by glucosamine in  DU145 cells Figure 2
Induction of the p21/WAF1 expression by glu-
cosamine in DU145 cells. A and B, Cells were cultured 
either without or with 2 mM glucosamine. A, p21 protein 
levels assessed by ELISA 48 h after glucosamine treatment; B, 
p21 mRNA levels were determined by Northern blot 10, 25, 
and 35 h after glucosamine treatment, representative blot 
from three independent experiments with similar results is 
shown. C, cells were transfected with human (hp21CAT) and 
rat (rp21JFCAT) p21 promoter reporter plasmids in the 
absence or presence of 1 mM glucosamine and processed for 
CAT activity assay 48 h later. A and C, the results of a repre-
sentative experiments were presented as mean ± standard 
deviation of the three independent samples. All experiments 
were repeated at least three times.
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with p21 promoter reporter plasmids in the presence or
absence of glucosamine. We found that 1 mM glu-
cosamine induced both the human and rat p21 promoter
activities in the cells (Fig. 2C) indicating that the p21 gene
is a transcriptional target of glucosamine. These results
suggest that the up-regulation of p21 underlies glu-
cosamine-induced inhibition of G1-S transition (Fig. 1C).
Glucosamine induces cell death in DU145 cells
We estimated percentages of dead cells by trypan blue
staining after treatment of DU145 cells with four different
concentrations 1, 2, 4, or 8 mM of glucosamine for two
days. As shown in Fig. 3A, glucosamine induced cell death
in a dose-dependent manner and a significant percentage
of dead cells were detected even at 1 mM concentration. It
notes that the effect on cell death reached to plateau with
approximately 40% of dead cells at 8 mM concentration.
To study the nature of cell death, apoptosis assays were
carried out. Treatment with 2 mM glucosamine for 24 h
resulted in 3-fold increase in DNA fragmentations as
detected by ELISA apoptotic cell death assay (Fig. 3B).
Glucosamine-induced apoptosis was further confirmed
by flow cytometry analysis after annexin V staining of glu-
cosamine-treated cell culture (data not shown). Taken
together, our results show that glucosamine exerts anti-
cancer activities in DU145 cells through at least two path-
ways by inhibiting cell proliferation and stimulating cell
death.
Glucosamine inhibits STAT3 signaling pathway in DU145 
cells
Proliferation of DU145 cells in vitro is stimulated by inter-
leukin-6 (IL-6) in an autocrine manner [22] and is associ-
ated with constitutive activation of STAT3 signaling
pathway [14]. The blockage of STAT3 in these cells by
either antisense oligonucleotides or dominant negative
STAT3 proteins was shown to inhibit cell proliferation
and induce apoptosis [14]. These data led us to examine
whether glucosamine affects STAT3 pathway. When acti-
vated, STAT3 is phosphorylated, and the DNA binding
and transcriptional activities are enhanced to stimulate
cell proliferation and survival. We assessed phosphoryla-
tion of STAT3 at the Tyr705 residue by Western blot anal-
ysis, DNA binding activity by EMSA, and transcriptional
activity by transient transfection assays. For the phospho-
rylation, DU145 cells were treated with 2 mM glu-
cosamine for 2, 4, 8, 12 or 24 h and the whole cell lysates
were analyzed by Western blotting using antibodies spe-
cific to phosphorylated and nonphosphorylated STAT3
proteins. The results showed that glucosamine treatment
gradually decreased the phosphorylation at the Tyr705
residue for 8 hours, and the lower phosphorylation levels
were sustained for up to 24 h (Fig. 4A). Dose-dependent
experiments revealed a clear decrease of STAT3 phospho-
rylation at Tyr705, but phosphorylated STAT3 did not dis-
appear completely even under 8 mM concentration
(Additional file 1). On the contrary, the treatment did not
affect the quantity of total STAT3 proteins for at least 24 h;
therefore, the diminished phosphorylation at the Tyr705
residue is not the consequence of the down-regulation of
STAT3 proteins.
To examine in vitro STAT3 DNA binding activity, EMSA
was performed with a mixture of a radioactive oligodeox-
yribonucleotide probe specific to STAT3 and nuclear
extracts from DU145 cells treated with 2 mM glucosamine
for 1, 4, and 8 h (Fig. 4B). A complex formation between
STAT3 proteins and the probe indicated by an arrowhead
(lane 2), disappeared in the presence of an excess of the
non-radioactive probe (lane 6), but not with an excess of
Induction of DU145 cell death by glucosamine Figure 3
Induction of DU145 cell death by glucosamine. A, 
DU145 cells were cultured in the absence or presence of 1, 
2, 4 or 8 mM glucosamine for 2 days in 24-well plates. Per-
cent of dead cells was examined by trypan blue staining. B, 
apoptosis in DU145 cells after treatment with 2 mM glu-
cosamine for 24 h. The results of a representative experi-
ment are presented as mean ± standard deviation of the 
three independent samples. All experiments were repeated 
at least three times.
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the non-specific oligodeoxyribonucleotide (lane 7). The
complex was super-shifted with the specific anti-STAT3
antibody (lane 8). This data demonstrated that the com-
plex formation is specific between STAT proteins and the
probe. The formation was reduced with glucosamine
treatment in a time-dependent manner; almost no
changes were observed 1 h after the treatment (lane3),
and the complex formation was considerably reduced 4 h
(lane 4) and remained lower 8 h (lane 5) after the treat-
ment. It seems that the reduction in phosphorylated
STAT3 (Fig. 4A) is consistent with that in the DNA bind-
ing activity (Fig. 4B).
To study the effects of glucosamine on the STAT3 tran-
scriptional activity, we carried out transient transfection
assays using the reporter plasmid pSTAT3-Luc in which
the luciferase gene expression was under the control of
two STAT3 response elements. The plasmid pTA-Luc lack-
ing the STAT3 response element was used as a control
plasmid. After transfection with pSTAT3-Luc or pTA-Luc,
DU145 cells were treated with 1 mM glucosamine for 48
h and luciferase activity was measured (Fig. 4C). Glu-
cosamine treatment reduced the luciferase activity of
pSTAT3-Luc to 50% of that without the treatment, while
the treatment did not affect the luciferase activity in the
cells transfected with the control plasmid. These data
demonstrates that glucosamine suppresses the transcrip-
tional activity of STAT3 and can be an effective inhibitor
of STAT3 signal pathway in DU145 cells.
Glucosamine inhibits survivin gene expression in DU145 
cells
Since an apoptosis inhibitor survivin is a transcriptional
target of STAT3 and one of validated cancer therapeutic
target [23], we investigated whether the expression of sur-
vivin in DU145 cells was affected by glucosamine. The
total RNAs from the cells treated with 2 mM glucosamine
were isolated and analyzed by Northern blot as shown in
Fig. 5A. Survivin mRNA levels did not change for the first
10 hours, but were considerably decreased for 25 h and
remained lower levels for up to 35 h after glucosamine
addition. Survivin protein in total cell lysates was also
measured by enzyme immunometric assays. The treat-
ment of DU145 cells with 2 mM glucosamine for 35 h
reduced the amount of survivin protein to one-third of the
levels observed in non-treated cells (Fig. 5B). These find-
ings show that glucosamine is a suppressor of the survivin
gene expression. This effect likely occurs through suppres-
sion of STAT3 signaling and may contribute to cell prolif-
eration restraint and apoptosis observed in glucosamine-
treated cells.
Specificity of glucosamine-induced inhibition of cancer cell 
proliferation
To examine whether glucosamine effects on the suppres-
sion of cell proliferation is specific to STAT3 pathway in
DU145 cells, we investigated effects of glucosamine in
three additional cancer cell lines, prostate carcinoma PC-
3 and C4-2B cells and cervix carcinoma Hela cells, in
which different signaling pathways are activated. In addi-
Glucosamine inhibits STAT3 activity in DU145 cells Figure 4
Glucosamine inhibits STAT3 activity in DU145 cells. 
A, Control and glucosamine-treated cells were grown in 6-
well plates either without or with 2 mM glucosamine and 
whole-cell extracts were analyzed by Western blot 2, 4, 8 
and 24 h after glucosamine treatment. B, EMSA. Lane 1, free 
probe without nuclear proteins. Lanes 2-5, binding of the 
STAT3 radioactive probe to nuclear proteins from DU145 
cells, untreated (lane 2) or treated with 2 mM glucosamine 
for 1 h (lane 3), 4 h (lane 4) and 8 h (lane 5). Lane 6-7, com-
petition assay with 100-fold molar excess of non-radioactive 
STAT3-specific competitor (lane 6) or nonspecific competi-
tor (lane 7). Lane 8, nuclear proteins from untreated DU145 
cells incubated with STAT3-specific antibody before incuba-
tion with radioactive probe. Representative data from three 
independent experiments with similar results is shown. C, 
cells were transfected with pSTAT3-Luc luciferase reporter 
plasmid under the control of STAT3 responsible element, or 
control pTALuc plasmid, and were cultured without or with 
1 mM glucosamine for 48 hours before luciferase activities 
were measured in cell extracts. The results are presented as 
mean of three independent experiments ± standard devia-
tion.
B
C
0
0.2
0.4
0.6
0.8
1
1.2
1.4
pStat3Luc pTALuc Control
Reporter plasmids
L
u
c
 
a
c
t
i
v
i
t
y
 
(
f
o
l
d
 
s
u
p
p
r
e
s
s
i
o
n
)
 
No GlcN 1mM GlcN
8 h 4 h 0 h
234 5 17 68
Stat3
2 mM GlcN
1 h
Controls
A
p(Y705)Stat3
Stat3
Actin
2 mM GlcN
0 h 24 h 4 h 8 h 12 h 2 hCancer Cell International 2009, 9:25 http://www.cancerci.com/content/9/1/25
Page 6 of 11
(page number not for citation purposes)
tion to STAT3 pathway, well studied cell-signaling path-
ways associated with cell proliferation and survival, such
as phosphatidylinositol 3-kinase (PI3K)/Akt and
mitogen-activated protein kinases (MAPK), were investi-
gated. We compared the phosphorylation levels of STAT3
(Tyr-705), Akt (Ser-473), and Extracellular-Signal-Regu-
lated Kinase ERK1/2 (p44/42 MAPK) (Thr202/Tyr204),
since the phosphorylation of these proteins is co-related
with the activation of corresponding pathways. These can-
cer cells were treated with 2 mM glucosamine for 18 h and
whole-cell extracts were used for Western blot analysis. As
shown in Fig. 6A, in DU145 and Hela cells all three sign-
aling pathways were constitutively activated, but the treat-
ment mainly suppressed the STAT3 phosphorylation. In
contrast to these cells, in PC-3 and C4-2B cells only PI3K/
Akt pathway was constitutively active and the treatment
did not change phosphorylation levels of Akt (Ser473). It
concludes, therefore, that glucosamine specifically inacti-
vates STAT3 pathway, but has almost no effects on PI3K/
Akt and ERK pathways under the conditions. This conclu-
sion is consistent to the analysis of cell proliferation (Fig.
6B) showing that glucosamine is an effective inhibitor of
proliferation only in cells where STAT3 pathway is active,
but ineffective in cells where the pathway is not active.
Discussion
Although anticancer activity of glucosamine was shown
more than 50 years ago [6], molecular mechanisms of its
actions remained unclear [8,10]. By testing human pros-
Suppression of survivin expression in DU145 cells by glu- cosamine Figure 5
Suppression of survivin expression in DU145 cells by 
glucosamine. A and B, cells were cultured either without 
or with 2 mM glucosamine. A, survivin mRNA levels were 
analyzed by Northern blot 10, 25, and 35 h after glucosamine 
treatment. The representative blot of three independent 
experiments is shown: B, survivin protein level were ana-
lyzed 35 h after glucosamine treatment by human total Sur-
vivin enzyme immunometric assay kit. The results are 
presented as mean ± standard deviation of three independ-
ent experiments.
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Inhibition of cancer cells growth by glucosamine is 
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tate cancer cell lines, we have found that glucosamine
dose-dependently suppresses proliferation and increases
apoptosis, and these anti-proliferative effects depend on
the status of STAT3 pathway in these cells. We show here
that glucosamine specifically inactivates STAT3 signaling
pathway and restrains the proliferation of cells expressing
constitutively activated STAT3, but is ineffective in cells
that do not have the activated pathway.
STAT3 is a transcription factor that stimulates cell prolifer-
ation and survival, and frequently exhibits constitutive
activity in different types of human tumors including
prostate, lung and breast cancers. Intervention of activated
STAT3 is a promising therapy to treat malignant cancers
[12,17]. STAT3 normally resides in the cytoplasm. After
phosphorylation of the Tyr705 residue, STAT3 dimerizes
and translocates to the nucleus where it binds to the spe-
cific DNA sequences to control transcription of several cell
cycle- and apoptosis-regulatory genes [11]. Blocking the
pathway by either antisense oligonucleotides or domi-
nant-negative proteins induced growth retardation and
apoptosis in DU145 cells [14,24]. In this study we dem-
onstrate that glucosamine suppresses the phosphoryla-
tion of STAT3 (Tyr705), thereby inhibiting its DNA
binding and transcriptional activities, and retards the pro-
liferation of DU145 and Hela cells (Fig. 6B) and the leuke-
mia K562 cells (our unpublished data and ref. 10), all of
which express constitutively active phosphorylated
STAT3. However, glucosamine did not affect the prolifer-
ation of PC-3 and C4-2B cells, in which STAT3 pathway is
not active (Fig. 6A). Our findings are in good agreement
with the recent publication reporting that glucosamine
inhibited proliferation, and restrained cell cycle G1-S
phase transition of DU145 cells, but did not have any
major effects in PC-3 cells [25].
We demonstrate that expression of genes controlling cell-
cycle and apoptosis such as p21, p27 and survivin is
affected by glucosamine treatment. Glucosamine-induced
arrest of DU145 cells at G1 phase could be partially due to
up-regulation of p21 through the inactivation of STAT3
pathway. Indeed, it was reported that over-expression of
p21 in DU145 cells blocked G1-S progression [26] and
that inactivation of JAK3/STAT pathway in cancer cells
increased p21 expression [27]. Thus, it is likely that
observed induction of p21 by glucosamine in DU145 cells
is a consequence of glucosamine-induced STAT3 inactiva-
tion. In contrast to the p21 expression, glucosamine
reduced p27 mRNA levels in DU145 cells (our unpub-
lished results). Similar p21 and p27 expression patterns
were reported by others in renal mesangial cells treated
with glucosamine [28]. Reduced expression of survivin
should contribute to the increase of apoptosis by glu-
cosamine. Since survivin gene expression is under control
of STAT3, it is reasonable to conclude that the expression
is down-regulated by inactivation of STAT3 signaling with
glucosamine treatment. Taken together, the present study
demonstrates that anticancer action of glucosamine is at
least in part due to the blockage of STAT3 signaling path-
way. Glucosamine may not be a very potent STAT3 inhib-
itor; fig. 3A showed less than 50% cell death after
treatment with 8 mM glucosamine and fig. 4A revealed
the presence of residual phosphorylated STAT3 after treat-
ment with 2 mM glucosamine for 24 h. These results sug-
gest that there could be more than two pathways to
activate STAT3 in DU145 cells, one sensitive and the other
not sensitive to glucosamine treatment (further discussed
below). It might be possible that this residual active
STAT3 could support survival of the remaining cells and
therefore, more inhibition of STAT3 phosphorylation
would be required for death of more tumor cells. How-
ever, glucosamine may have an application for the treat-
ment of tumors with constitutively active STAT3, because
it has several unique features as a putative therapeutic
agent. First, glucosamine has a low toxicity as proven for
many years by taking to ease symptom of pain related to
osteoarthritis [5]. Second, preferential uptake by tumor
cells is expected, since glucosamine is transported into
cells through glucose transporters that are much more
active in cancer cells than normal cells [29]. Third, glu-
cosamine enhances the potency of anticancer agents in
cancer cells [[30], and our unpublished results]. Taken
into account of all, we believe that glucosamine warrants
further study as a therapeutic agent.
Molecular mechanisms underlying the inhibition of
STAT3 activity by glucosamine remain to be determined.
STAT3 is phosphorylated on the tyrosine 705 residue by
three types of kinases: receptor tyrosine kinases such as
EGFR, FGFR and platelet-derived growth factor receptor
(PDGFR), Janus kinase (JAK) family members which con-
stitutively bind to cytokine receptors, or cytoplasmic
kinases including Src and Abl [12]. Protein tyrosine phos-
phatases such as the SH2-domain containing family can
directly dephosphorylate active STAT3. Glucosamine
might deactivate or activate these kinases or phos-
phatases, respectively to de-phosphorylate STAT3 pro-
teins. It has been shown that glucosamine increases O-
glycosylation of nuclear and cytosolic proteins which
modifies their functions [4,31]. It is therefore plausible
that proteins involved in these kinase and phosphatase
reactions could be modified by O-glycosylation and affect
indirectly STAT3 signaling. Alternatively, STAT3 itself is
modified by O-glycosylation in HC11 mammary epithe-
lial cells by EGF [32] and in DU145 cells by glucosamine
(our unpublished results), but functional consequences
of this modification are to be determined. Additionally,
glucosamine could suppress the protein functions
through inhibition of protein N-glycosylation as reported
for influenza virus hemagglutinin [33] and COX-2 [34].Cancer Cell International 2009, 9:25 http://www.cancerci.com/content/9/1/25
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Since many receptors including growth factor and
cytokine receptors are N-glycosylated, it is conceivable
that glucosamine could inactivate their functions by inhi-
bition of N-glycosylation thereby suppressing STAT3 sign-
aling.
Conclusion
Studies on the effects of glucosamine on human prostate
carcinoma DU145 cells in vitro identified several molecu-
lar events in its anti-tumor activity: up-regulation of CDK
inhibitor p21waf1/cip expression, down-regulation of
apoptosis inhibitor survivin and the most important sup-
pression of STAT3 signaling pathway. STAT3 is activated
in many different cancers including colon, breast and
prostate cancers. The activation often is associated with
transition from hormone-sensitive to hormone-refractory
prostate cancer and promotes its metastatic progression.
In addition, activated STAT3 stimulates survival and pro-
liferation of tumors. Although more work is required to
fully understand mechanisms of anticancer action of glu-
cosamine, this study provides the basis for the potential
application of glucosamine as an inhibitor of STAT3 sign-
aling pathway in cancer cells.
Methods
Cell lines and reagents
The human prostate cancer DU145 and PC3 and cervical
cancer HeLa cell lines were obtained from the American
Type Culture Collection. The human prostate cancer C4-
2B cell line was purchased from ViroMed Laboratories
(Minnetonka, MN). Cells were cultured in Eagle's mini-
mum essential medium supplemented with glutamine,
essential amino acids, 10% fetal bovine serum and antibi-
otics (100 units/ml penicillin G and 100 units/ml strepto-
mycin sulfates). Cells were incubated at 37°C in 5% CO2,
and the medium was changed every 3-4 days. Cells were
passaged at 70% confluent using trypsin/EDTA. D-Glu-
cosamine hydrochloride and trypan blue solution were
purchased from Sigma Chemical Co. (St. Louis, MO). Spe-
cific phosphatidylinositol 3-kinase inhibitor LY294002
and inhibitor of MAP kinase kinase (MEK) PD98059 were
purchased from Calbiochem (La Jolla, CA).
Cell growth and cell death assays
Cells in exponential growth were harvested, plated at a
density of 3 × 104 cells per well in 24-well flat-bottomed
plates (Corning, Inc., Corning, NY) for 24 h, fed with
fresh medium and treated with different concentrations of
glucosamine. After 2 and 3 days, both floating and
attached cells were harvested by trypsinization and col-
lected by centrifugation. Cell pellets were resuspended in
fresh media, and trypan blue solution was added at a ratio
of 1:1. The total and trypan blue-positive (blue) cells for
each well were counted using a hemocytometer. The total
cells were expressed as cell number per well. The blue cells
were considered dead and were counted as a percentage of
300 the total cells. Cell growth was also examined by
colorimetric assay of cell proliferation with cell prolifera-
tion kit I (MTT) (Roche Applied Science, Indianapolis, IN)
according to the manufacturer's protocol. Cells were
plated in triplicate at a density of 2.5 × 103 cells/well in
100 ul culture medium containing various tested com-
pounds into 96 well flat bottom microplates and the
effects of compounds on cell growth were measured by 1,
2 or 3 days after plating. Data was presented as mean ±
standard deviation (SD) of the three wells. Each cell line
and each compound was analyzed in three independent
experiments.
DNA synthesis assay
DNA synthesis was determined by measurement of bro-
modeoxyuridine (BrdU) incorporation into DNA via a
nonradioactive colorimetric assay using ELISA (Roche
Applied Science, Indianapolis, IN). Cells in exponential
growth were harvested and plated at a density of 3 × 103
cells per well in 96-well flat-bottomed plates (Corning,
Inc., Corning, NY) for 24 h. Cells were fed with fresh
medium and then treated with 1, 2 or 4 mM hexosamines.
The amount of incorporated BrdU over a 2 h period was
measured at 6, 14 and 24 h after the hexosamine treat-
ment. The assay was carried out according to the manufac-
turer's protocol. The substrate reaction was measured
without a stop solution at 370 nm on a spectrophotome-
ter. For each treatment and time point three wells were
used. The data was presented as mean and standard devi-
ation (SD) of the three independent wells.
Cell cycle analysis
Cells were plated at a density of 1.5 × 104 cells per cm2 in
a 250 ml tissue culture flask (BD Bioscience, MA). After 24
h, cells were fed with fresh medium and treated with 4
mM GlcN. Both adherent and detached cells were col-
lected by trypsinization, washed in PBS and fixed in ice-
cold 80% ethanol for at least 2 h. Fixed cells were centri-
fuged at 400 × g and resuspended in propidium iodide
(PI) stain buffer (0.3% Nonidet NP-40, 0.5 mg/ml of
DNase-free RNase A and 0.05 mg/ml of PI in PBS) for 30
minutes. After staining, the samples were analyzed by a
flow cytometer with the fluorescence-activated cell sorter.
Quantification of apoptosis
Apoptosis in DU145 cells was quantified by detection of
mono- and oligonucleosomes in the cytoplasm of cells by
photometric enzyme immunoassay with the Cell Death
Detection ELISA plus kit (Roche Applied Science, Indian-
apolis, IN) according to the manufacturer's protocol. Cells
were cultured in a 24 well plate for 24 h, and then treated
with 2 mM GlcN for 24 h. Both floating and adherent cells
were used for assays. The samples were analyzed in dupli-
cate in three independent experiments. Results were meas-Cancer Cell International 2009, 9:25 http://www.cancerci.com/content/9/1/25
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ured by absorbance at 405/490 nm and expressed as a fold
of induction of DNA fragmentation relative to the control
without GlcN treatment.
Protein immunoassays
The quantification of p21/WAF1 protein in DU145 cells
was performed by the p21WAF1 ELISA kit (EMD Bio-
sciences, Inc, San Diego, CA, Cat. No. QIA18) according
to the manufacturer's protocol. The samples were ana-
lyzed in duplicate in three independent experiments.
Optical absorbance was measured at 450-550 nm and
expressed as p21 amount relative to controls without
GlcN treatment. For the quantitative determination of sur-
vivin, the human Total Survivin Enzyme Immunometric
assay kit (Assay designs Inc, Ann Arbor, MI, Cat. No. 900-
111) was used. The cells were lysed directly in the wells of
6-well plates and analysis of lysates was performed
according to the manufacturer's protocol. The samples
were analyzed in duplicate in three independent experi-
ments and optical absorbance was measured at 450 nm
and expressed as survivin arbitrary units.
RNA extraction and Northern blotting
Cells were lysed in a culture dish with TRIzol reagent (Inv-
itrogen Corporation Carlsbad, CA) by using 2 ml per 50-
75 cm2 and RNA was isolated according to the manufac-
turer's recommendations. For Northern blot analysis, 15
μg of total RNA were electrophoresed on 1% agarose-for-
maldehyde gels, transferred to Nylon filters (Zeta-Probe
GT; Bio-Rad Laboratories, Hercules, CA), ultraviolet cross-
linked (Stratagene, La Jolla, CA), and hybridized with a
P32-labeled single strand DNA probe in the ULTRAhyb
hybridization buffer (Ambion, Austin, TX).
The probes were made by PCR reaction using cDNAs tem-
plate, one sequence-specific primer, dNTPs and P32-
labeled α-dNTP (mainly dCTP). After washing, filters were
exposed for autoradiography at -70°C with a BioMax
screen (Eastman Kodak, Rochester, NY).
Transient transfection analysis
The human CAT reporter plasmid was constructed by
inserting a 2.7 kB PCR fragment of the human p21 pro-
moter region (-2583/+110) in the pCAT Basic plasmid
(Promega Corporation, Madison, WI). The rat CAT
reporter plasmid (p21JFCAT) with a 4.7 kB rat p21 pro-
moter region in the pJFCAT plasmid was a gift from Dr.
Bert Vogelstein. STAT3 transcriptional activity was exam-
ined by transient transfection assays of the pSTAT3-Luc
reporter plasmid. As a control, the pTA-Luc plasmid which
does not carry STAT3 responsible DNA elements was
used. Both the pSTAT3-Luc and pTA-Luc plasmids were
purchased from Panomics Inc. (Fremont, CA, Cat. No.
LR0077 and LR0000). For transfection, DU145 cells were
plated at density of 2 × 105cells per well in 6-well flat-bot-
tomed plates (Corning, Inc, NY) for 24 h. One hour
before transfection, the cells were fed with fresh medium
with 1 mM GlcN. Transfections were performed in tripli-
cate using the siPORT XP-1 transfection agent (Ambion
Inc., Austin) with 0.7 μg of the reporter or control plasmid
and 0.3 μg of the β-Gal reporter plasmid. The cells were
harvested in a Reporter lysis buffer (Promega Corpora-
tion, Madison, WI) 48 h after the transfection and used for
CAT, Luciferase and β-Gal activity assays. All transfection
were analyzed in three independent experiments and
results were expressed as a fold of reporter gene activation
or suppression relative to the controls without GlcN treat-
ment.
Immunoblotting
Control and glucosamine-treated cells were grown in 6-
well plates. After removing the culture medium, cells were
washed with 1 × PBS and then lysed in the wells with 0.2
ml of RIPA lysis buffer (25 mM Tris:HCl, 150 mM NaCl,
1% NP-40, 1% Sodium deoxycholate, 0.1% SDS, pH 7.6)
supplemented with protease and phosphatase inhibitors
(Santa Cruz Biotechnology, Santa Cruz, CA) for 15 min at
4°C. Lysates were transferred to 1.5 ml microcentrifuge
tubes, vortexed at maximum speed for 15 sec to shear
DNA and centrifuged at 12000 g for 10 min at 4°C. Super-
natants were quantified for protein concentrations by
BCA protein assay kit (Pierce Biotechnology, Rockford,
IL). Immunoblotting was performed after SDS-PAGE of
equal amounts of proteins on 10% precast gels (Pierce,
Rockford, IL, Prod # 25204) and were detected using
horseradish peroxidase-conjugated antibody and Western
blotting luminol reagent (Santa Cruz Biotechnology,
Santa Cruz, CA). Antibodies to STAT3, phospho-STAT3
proteins, phospho-Akt (Ser 473) phospho-p44/42 MAPK/
ERK1/2 and actin were purchased from Cell Signaling
Technology, Inc, (Beverly, MA).
EMSA
Nuclear extracts were prepared by lysing nuclei in a high-
salt buffer supplemented with protease and phosphatase
inhibitors (Nuclear extraction kit, Panomics, Fremont,
CA, and Cat. No. AY2002) according to the manufac-
turer's protocol. Protein concentrations were quantified
by the Bio-Rad protein assay (Bio-Rad Laboratories, Her-
cules, CA). Nuclear extracts (10 μg) were incubated in a
final volume of 20 μl of 10 mM HEPES (pH 7.5), 50 mM
KCl, 10% glycerol, 4 mM spermidine, 100 μg/ml polydI-
dC and the P32-labeled double-strand oligodeoxyribonu-
cleotide with a STAT3 binding motif AGCTTCATTTCCCG-
TAAATCCCTA (36) for 20 min at room temperature. For
the supershift analysis, nuclear extracts were preincubated
with the anti-STAT3 antibody (Chemicon International,
Temecula, CA) for 20 min at room temperature. DNA-
protein complexes were electrophoresed on 4.5% nonde-
naturing polyacrylomide gels with 0.5 × TBE buffer con-Cancer Cell International 2009, 9:25 http://www.cancerci.com/content/9/1/25
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taining 2.5% glycerol at room temperature and
autoradiophographed.
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STAT: signal transducer(s) and activator(s) of transcrip-
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transporters; BrdU: bromodeoxyuridine; SD: standard
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